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Abstract
Cytotoxic agents, also called antineoplastic agents, are used in cancer treatment due to their inherent activity to
inhibit cell growth or proliferation, or DNA, RNA and protein synthesis. They are, therefore, hazardous by nature in
a non-selective manner leading to disruption of cell growth and function of both diseased and healthy cells of treated
patients.
While the benefits of receiving cytotoxic agents may outweigh the incurred risks for patients, the same cannot be said
for exposed healthcare practitioners involved in the transport, preparation, administration, and resulting waste disposal
of these agents.
Consequently, many professional bodies around the world have set standards of practice to prevent occupational
exposure of healthcare workers to cytotoxic agents, and hospitals have been active in defining strict policies in this
concern.
However, due to the variability of the practice and infrastructure in academic settings, some activities
performed within the cytotoxic academic research laboratory often do not adhere to recommendations published
by guidelines.
The present recommendations were therefore set forward by members of a working group who are experts on the
subject matter representing academic, clinical, and research backgrounds in an attempt to promote safe cytotoxic
handling in academic institutions.
The document maps out the trajectory of cytotoxic agents being investigated in academic research laboratories
while providing recommendations on the delivery, storage, use and disposal of cytotoxic agents in university settings.
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Cytotoxic agents (CAs), also called antineoplastic
agents, are used in cancer treatment due to their inher-
ent activity to inhibit cell growth or proliferation, or
DNA, RNA and protein synthesis. They are, therefore,
hazardous by nature in a non-selective manner leading
to disruption of cell growth and function of both dis-
eased and healthy cells of treated patients.1
While the benefits of receiving CAs may outweigh
the incurred risks for patients, the same cannot be said
for exposed healthcare practitioners involved in the
transport, preparation, administration, and resulting
waste disposal of these agents.
Consequently, many professional bodies around the
world have set standards of practice to prevent occu-
pational exposure of healthcare workers to CAs, and
hospitals have been active in defining strict policies in
this concern.
However, due to the variability of the practice and
infrastructure in academic settings, some activities per-
formed within the cytotoxic academic research labora-
tory (CARL) do not adhere to recommendations
published by guidelines.
This was highlighted in a national survey gauging
current practices of cytotoxic handling within CARLs
in the United Kingdom.2
Results revealed that due to the lack of CARL tai-
lored guidelines, many safety considerations are
overlooked.
The present recommendations were therefore set
forward by members of a working group who are
experts on the subject matter representing academic,
clinical, and research backgrounds in an attempt to
promote safe cytotoxic handling in academic
institutions.
It must be noted that these recommendations should
be followed alongside the policies and procedures of
the organization and the national and/or federal ones
in place.
Scope
This document is aimed at
• Safety officers, laboratory managers, cleaning super-
visors, waste disposal personnel, store reception, and
goods in (also called Procurement) managers work-
ing in universities where research involving cytotoxic
or potentially cytotoxic agents is carried out
• Research supervisors, researchers, and students
involved in handling cytotoxic or potentially cyto-
toxic agents.
Oncology is a research-driven specialty whereby
understanding the science underpinning practice and
investigating interventions to optimise this practice
advance the field. A significant proportion of oncology
research is conducted in academic research settings and
this can vary from cancer drug discovery, formulation
research to practice research.
Thus, the handling of CA in academia is frequent
and vital for supporting advances in cancer care.
Researchers in academic institutions often conduct
analytical or animal testing on CAs to enhance their
clinical use or suggest new treatment patterns.
Additionally, the synthesis of compounds with poten-
tial cytotoxic activities often takes place in chemistry
labs of academic institutions. All these research activ-
ities are taking place in laboratories not dedicated nor
engineered for cytotoxic handling.
The document maps out the trajectory of CAs and
potentially CAs investigated in academic research lab-
oratories while providing recommendations covering
the gaps related to the safe delivery, storage, use and
disposal of CAs in university settings. This document
does not aim to provide specific recommendations on
the type of personal protective equipment (PPE), bio-
logical safety cabinets (BSC), and other items used in
the handling of CAs. Reference to updated guidelines
from national and international societies should be
sought for this purpose (e.g. ASHP, ISOPP).
Recommendation development method
The working group met on a quarterly basis; first, the
framework of the guidance was set during introductory
meetings, then members were divided into task-
orientated sub-groups that addressed specific elements
of the proposed recommendation. Resources were
shared between members to facilitate access to pub-
lished guidance on cytotoxic drug handling. Finally,
preliminary drafts were submitted and discussed for
consensus.
Glossary
The definitions used in this guidance have been
adopted from national and international organizations
where available. Otherwise, the authors have developed
their own definitions as listed below
1. Accident: an event that results in injury or ill health 3
2. Audit: an in-depth review of an organisation’s safety
management structure and operational procedures
3. Could: used for providing suggestions from expert
opinion
4. Closed system drug-transfer device (CSTD) as
“a drug transfer device that mechanically prohibits
2 Journal of Oncology Pharmacy Practice 0(0)
the transfer of environmental contaminants into the
system and the escape of hazardous drug or vapour
concentrations outside the system” 4
5. CARL is defined as any laboratory in a university
or research centre where cytotoxic agents, classified
as hazardous, are manipulated, temporarily or per-
manently, to investigate and enhance drug
properties.
a. A dedicated CARL is defined as a specialist
laboratory where only CAs are investigated.
b. A temporary CARL is defined as a general-
purpose laboratory with temporary use of
equipment within for CA investigation.
Examples of temporary CARLs include but are not
restricted to
(i) Chemistry research laboratories that are sometimes
used for the synthesis of new compounds with
potential cytotoxic activities. These compounds
should be treated as cytotoxic until proven other-
wise as dictated by the National Institute for
Occupational Safety and Health (NIOSH) defini-
tion of hazardous drugs5
(ii) Animal testing laboratories
This guidance is limited in targeting the laboratories
for animal testing as there are specific guidances that
target this matter within its scope 6,7
Where cytotoxic agents are tested on animals held in
cages, special attention should be addressed to the
excrement and carcasses. These need to be treated as
cytotoxic waste. Other safety issues, such as the con-
trolled laboratory access, PPE, waste disposal, etc.
should be addressed as dictated in this guidance.
When the referenced guidance on animal testing
above and the present one target the same matter, the
more vigilant guidance overrides.
(iii) Cell culture laboratories
(iv) Instrumentation laboratories; containing HPLC,
NMR, etc.
Activities undertaken in these laboratories may
include but are not restricted to the following: synthesis
of potentially cytotoxic compounds, storage of CA vials
and ampoules, reconstitution of CA, dilution of CA from
concentrated solutions, transferring CA into tubes or
glass vials for chemical analysis, running CA samples in
analytical chemistry equipment, animal testing with CA,
animal retention in cages, cage wash facilities, etc.
6. Cytotoxic agents: “all drugs with direct anti-tumour
activity, including conventional anti-cancer agents,
monoclonal antibodies and partially targeted
agents (e.g. kinase inhibitors, such as sunitinib, ima-
tinib), and drugs such as thalidomide and
lenalidomide.” 8
Cytotoxic agents are classified as hazardous which is
defined by the NIOSH5 as “those that exhibit one or
more of the following six characteristics in humans or
animals:
• Carcinogenicity
• Teratogenicity or other developmental toxicity
• Reproductive toxicity
• Organ toxicity at low doses
• Genotoxicity
• Structure and toxicity profiles of new drugs that
mimic existing drugs determined hazardous by the
above criteria”
7. Detergent¼cleaning agent with wetting agent and
emulsifying-agent (tensio active) properties.
8. Goods in: it is the department which handles, deliv-
ers, distributes, and processes the goods and parcels
delivered to the academic organization
9. General store refers to the storage section in the
academic organization
10. Incident:
a. near miss: an event not causing harm, but has
the potential to cause injury or ill health 3
b. undesired circumstance: a set of conditions or
circumstances that have the potential to cause
injury or ill health,3 e.g. untrained personnel
handling CA
11. Laboratory Containment levels
The Advisory Committee on Dangerous Pathogens
(ACDP) have set three laboratory containment levels
to ensure the safety of the workers and community in
all research, teaching, clinical, forensic, veterinary and
environmental organizations.9
A CL1 laboratory is suitable for secondary educa-
tion and undergraduate teaching where biological
agents unlikely to cause disease in healthy humans
are handled.
A CL2 laboratory is assigned for clinical,
diagnostic and research work involving low to moder-
ate risk biological agents, those with accessible effective
prophylaxis and treatment, and unlikely to be
transmitted.
The highest containment level is a CL3 laboratory
offering satisfactory protection to workers and other
members of the community from the direct effect or
transmission of hazardous biological agents.
12. Should: used to say or ask what is correct or best
thing to do.10 It is used to show an obligation.
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Recommendation sections
1. Goods in
When ordering a CA, the researcher should make sure
the delivery package is delivered only through goods in
of the relevant organization and not bypass it regard-
less of how small the quantity is.
1.1. Reception of CAs in goods in department:
1.1.1. The researcher should inform the goods in and
the store when expecting to receive a CA. Not all CA
packages received are usually labelled with a hazard
caution sign; however, requesting the sender to label
it might fall outside of the requirements of labelling.
Hence, the procurement at the university could agree
with the supplier to label the packaging accordingly.
1.1.2. The staff at goods in should be aware that they
are receiving a CA and should be briefed on their pos-
sible hazards. In particular, it should be recorded that
the package was not physically damaged upon recep-
tion. In case of evidence of physical damage on the
parcel, it should be accepted from the courier to
avoid exposing the driver to cytotoxic hazards, and
the safety officer should be notified. The damaged
parcel should be treated as a spill and disposed of as
per guidelines.
A risk assessment should be in place for the storage
of CAs including emergency procedures, which the
goods in and store staff should be familiar with.
1.1.3. Records of CA: Records indicating the below
should be maintained:
• The time and date of parcel receipt
• The name of the company delivering the CA
• The staff who accepted the delivery
• The type and amount of CA delivered
• The date of pick up by the researcher
• The physical state of the received package
This serves as a tracking system for occupational
exposure as well as for CA flow within university
premises.
Universities could consider having a stock tracking
system in place; this is a program that will track the use
and users of all CAs received and handled within uni-
versity premises in order to: (1) record researcher expo-
sure, (2) track consumption and depletion of the CA,
and (3) facilitate acquisition of the CA by other
researchers working on the same molecule.
1.2. Storage. CAs should be stored in a separate zone
within the storage area away from traffic, within a ded-
icated refrigerator or cabinet securely locked with lim-
ited access.
A mechanical digital lock should be considered to
lock the cabinet or refrigerator as the digits don’t
become discernible after repeated use as is the case
with electronic digital locks.
1.3. Qualification/training. Store reception and goods in
staff should have a basic knowledge of the hazardous
properties of CAs and receive training on the use of the
spill kit
1.4. PPE. The staff should wear adequate PPE when
handling parcels with visible signs of damage/spill.
The staff could be advised to wear PPE when handling
parcels that haven’t lost their integrity as a precaution-
ary measure.
1.5. Spill kit
An appropriate spill kit should be present in the store
near the CAs storage zone and should be used in case
of a spill or if there is sign of spill on the outer pack-
aging (refer to section 2.1 on spill kit content).
The store staff should not handle spillage or leakage,
rather they should post a sign to warn people not to go
near the contaminated area. Additionally, they should
know whom to contact and the area should be evacu-
ated if necessary.
The chemical safety officer or member of the depart-
mental safety team dealing with spillage and leakage
should be notified to deal with this event.
1.6. Incident reporting system. Classification: There
should be an incident reporting system in place, and
it should comply with the organisation’s reporting
process.
2. Transport
Within university premises; intact package(s) picked up
from ‘goods in’ could be transported to the laboratory
as they are, there is no need for a lab coat or PPE
2.1. Spill kits
A cytotoxic spill kit should be carried during transpor-
tation of CA vials and tubes within university premises.
The cytotoxic spill kit should enable quick and safe
access to remove commonly listed/used cytotoxics and
should comply with the requirements set forth by rec-
ognized guidelines such as AJHP or ISOPP.
The spill kit should contain the following items at
the least7
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• User’s instruction
• Warning signs
• Personal protective equipment: Impermeable protec-
tive gown, shoe-cover, head-cover, goggles/face
shields, respirator mask, Chemotherapy gloves
• Swabs
• Concentrated alkaline detergent solution
• Clearly labelled cytotoxic waste container.
• Spill report/incident form.
2.2. Leak proof containers
Leak proof solid containers with visible yellow hazard
labelling should be used for transporting cytotoxic
materials contained within test tubes or other contain-
ers (e.g. HPLC vials) within university premises. A leak
proof bag could be used as an alternative.
3. CARL
3.1. Classification
ACDP CL2 is a minimum requirement for laboratories
where CAs are handled.
3.2. Access
3.2.1. Signage. Appropriate signage should be clearly
posted on the external side of the entrance door to
indicate in non-scientific wording the type of exposure
within the laboratory. Moreover, the sign should also
highlight the fact that the CARL has restricted access
for that reason.
3.2.2. Restricted access. CARL access should be restrict-
ed to authorised personnel. This could be implemented
using access control. Moreover, any cleaning or main-
tenance work should not be performed without at least
notifying (if not the presence) of the laboratory man-
ager or authorised technical staff. Cleaners and main-
tenance staff should also go through induction before
accessing. Maintenance managers should liaise with
laboratory manager. There should be a process that
protects the integrity of the laboratory, equipment
and the safety of the staff.
3.2.3. Secure storage of cytotoxic agents. Cytotoxic agents
used within an institution should only be stored within
a dedicated CARL. Within the latter, there should be a
dedicated locked cabinet and/or fridge for storing
opened/unopened vials. Similarly, this applies to pre-
pared stock solutions and samples that could be stored
in a separate cabinet or fridge.
Except for unopened vials, everything should be
clearly labelled with date of preparation, date of
opening, name of cytotoxic agent, concentration and
initials of researcher.
3.3. Cleaning and maintenance works within CARL
3.3.1. Personnel:. Cleaners should be trained and super-
vised to perform cleaning.
Engineers should be provided with an induction
session.
For safety of the staff and integrity of the laborato-
ry, access to CARL should be sought before being
accessed by cleaning and maintenance staff.
3.3.2. PPE. The cleaning staff should use safety glasses/
appropriate eye protection or face shield (if possibility
of splashing), protective chemotherapy gloves, over-
shoes, and disposable gowns to protect their own
clothes. They should wash their hands thoroughly
with soap and water immediately after removing the
gloves.
3.3.3. Cleaning utensils. Dedicated cleaning utensils (e.g.,
wipers, mops, and disinfectants) for use in the clean-
room should be made of materials that generate a low
amount of particles. All cleaning tools should be non-
shedding and dedicated to use in the laboratory.11
A mop could be used and discarded as cytotoxic
waste, as an alternative, a disposable head/wipe could
be used to avoid worrying about storing of these ded-
icated utensils.
If cleaning tools are reused, their cleanliness should
be maintained by thorough cleaning and disinfection
after use and by storing in a clean environment between
uses. These should not be shared with other
laboratories.
3.3.4. Cleaning methodology.
Researchers are responsible for cleaning the work-
benches and surfaces. Cleaners are responsible for
cleaning the floor. Cleaning should take place when
no active experimentation is taking place. The labora-
tory manager should keep a log of cleaning activities.
Cleaning should proceed from the cleanest area to
the dirtiest area of the room. This would involve a ceil-
ing to floor cleaning flow, moving outward from the
ventilation tool to the exit.
BSC: Wipe the surface of the BSC including front,
sides and bottom in the direction of the groove of the
surface. Wiping should be in a continuous motion.
When a corner is met, the researcher should make an
‘S’ curve and return to the opposite side while over-
lapping the previous stroke. The researcher should con-
tinue with fixtures (e.g., gas or vacuum valves, bar and
hooks, if present), the sides, and finally the work
surface.
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3.3.5. Approved detergents. Agents, approved by the insti-
tution, should be used to deactivate cytotoxics.
3.3.6. Cleaning frequency. As per international guidelines,
equipment such as the BSC as well as work benches
should be cleaned after each use, and as such, left
clean. A comprehensive cleaning of the laboratory
should be scheduled periodically by the laboratory
manager.
3.3.7. Disposing of contaminated waste. Solid waste gener-
ated throughout cleaning or decontamination proce-
dures should be collected in suitable plastic bags,
sealed inside the ventilation tool, and removed with
minimal agitation. Cleaning solution used to clean
the floors could be discarded in the regular drains.
Liquid waste, such as that collected from test tubes,
and HPLC vials, should be collected in large glass
waste bottles, as they are impervious to most chemicals.
Care should be taken while handling the bottle as it
presents a breakage hazard, hence plastic (e.g., poly-
ethylene jerry cans) or metal (galvanized or stainless
steel) safety containers could be used.
The content and concentrations of liquid waste
should be clearly and safely labelled on the bottle.
Solid and liquid waste should be accumulated in the
CARL pending transfer to the institution’s central
facility for chemical waste handling
3.3.8. Safety cabinet checks/service. Containment during
changing filters: laboratory access should only be
granted when no active experiment is taking place
Documentation of education, training, exposure and
cleaning should be maintained
Engineers, carpenters and maintenance staff should
follow the same procedure as the cleaning personnel in
what concerns CARL access and PPE.
PPE comprising of shoe cover and gloves should be
used at all times
Replaced filters should be disposed of as contami-
nated waste
3.4. Laboratory rules
For each CARL, standard operating procedures (SOP)
should be developed and updated periodically. Within
one institution, if there is more than one CARL, then a
separate SOP should be developed for each CARL cus-
tomised to the type of agents, experiments, and equip-
ment used. However, the laboratory SOP should
adhere to the institution’s general guidance framework,
which might translate into common sections within
each SOP.
For example, common sections could include educa-
tion and training of researchers, reporting procedures,
record of employee exposure, environmental controls,
cleaning, personal contamination procedure etc.
3.5. Equipment
3.5.1. Engineering controls. Appropriate engineering con-
trols related to the type of investigations conducted
(such as Microbiological Safety Cabinet (MSC), fume
hoods, isolators) should be used in the CARL
3.5.2. Maintenance and service. The engineering controls
used should be well maintained and serviced to ensure
safe and effective use.
3.5.3. Closed system drug-transfer devices. Closed system
drug-transfer devices could be used when possible
4. Laboratories other than CARL used for
cytotoxic research; temporary CARL
4.1. Rationale
Cytotoxic research: all testing with CAs should be per-
formed in dedicated CARL, unless major equipment is
housed in other facilities (section D, definition 5-b)
4.2. Label
A clearly labelled, portable cytotoxic spill kit should be
available wherever CAs are being prepared, stored,
analysed and investigated.
4.3. Signage
Proper temporary signage informing all researchers of
the presence of CAs and their hazards should be dis-
played in highly visible locations and on the external
door while work is taking place. The warning should be
communicated in language easily understood by all
researchers (e.g. agent toxic to human cells in use).
This signage should specify the date, time and dura-
tion of the experiment, and should be removed at the
end of the experiment.
4.4. Work mats
Work mats, preferably with an under layer to guaran-
tee non-slip stability on work surfaces, should be used
in temporary CARLs for adequate absorption and con-
tainment of cytotoxic spills
4.5. Cleaning
4.5.1. Instruments. A clear ‘Instrument-specific’ cleaning
regime should be devised before use.
For instruments where parts are in direct contact
with the drug (e.g. HPLC), there should be a more
6 Journal of Oncology Pharmacy Practice 0(0)
rigorous regime than those where the sample is sealed
(e.g. NMR).
For HPLC and LC-MS, columns and tubing should
be flushed through with deionised water for an appro-
priate period after use.
Injection ports should be ‘activated’ five times using
deionised water.
Buttons, keyboards etc. should ideally be covered
with an appropriate overlay during use. If this is not
possible, they should be wiped thoroughly afterwards.
A keyboard protector readily available on the market
could also be used. As an alternative, a transparent
plastic bag could be used and later disposed of as cyto-
toxic waste after each use.
A separate eluent waste bottle labelled as cytotoxic
should be used and removed after the work is completed.
4.5.2. Workbenches. The immediate laboratory work
area should be cleaned with water and detergent soap
(not disinfectant) when the experimental procedures
are completed for the day, by the researcher him/her-
self. The laboratory area where cytotoxic agents are
used should not be utilized for any other purpose
until cleaning has been performed. Full PPE, as men-
tioned in section 5.3, should be used while cleaning the
area, and full PPE worn while running the experiment.
5. Researcher
5.1. Eligibility
Notice of occupational exposure and adequate training
(background, theoretical training, and practical train-
ing): All researchers involved in cytotoxic preparation
should be educated about the risks associated with
cytotoxic handling, and of the safe handling of CA
and related waste.
Exclusions from work in the cytotoxic laboratory/
risk assessment
Illness. The Medical team should be informed and a
decision on whether to carry on with this work
should be made after consideration of all possible
risks (e.g. in case the researcher is on long term medi-
cines that are carcinogenic).
Family planning for male and female researchers
Pregnancy, lactation
Medical examination. there are no current medical/labo-
ratory indicators robust enough to be used in assessing
the occupational exposure to CAs.
5.2. Training
5.2.1. Safe handling procedures. All researchers involved
in cytotoxic preparation should have completed a cer-
tified training conforming to the outlined sections/reg-
ulations. A person designated by the institution should
provide the standardized training; all education provid-
ed should be documented and related records retained.
A competency assessment of practice should be per-
formed on a yearly basis to verify compliance with
procedures (continuous professional development/
annual update); the assessment could be brief but dif-
ferent each year.
5.2.2. Content of training. The training should cover the
below points as a minimum requirement
• Safety cabinet/isolator
• Types of acceptable safety cabinets
• Proper use of safety cabinets
• Working in the laboratory (check laboratory eti-
quette in section 3- CARL)
• Use of PPE
• Handing cytotoxic waste
• Handling cytotoxic spill
• Cleaning procedures (after each work session and in
case of a spill)
• Manipulating cytotoxic vials
• Possible contamination on the outside of vials
• Withdrawing from cytotoxic drug vials
5.3. PPE
Types of PPE suitable for this area:
5.3.1. Gloves. Gloves should not be worn for more than
an hour and should be replaced immediately if there is
a visible tear or leak.12,13
Latex, nitrile or neoprene gloves could be used as
long as they meet the ASTM D6978-05 standards.6
Double gloves could be used when chemotherapy
gloves are not used.
Gloves should be taken off safely and discarded.6,7
When double gloves are worn, the inner pair
should be kept on to handle the analytical machinery
(HPLC, etc.).
5.3.2. Masks. Common surgical masks offer no protec-
tion against aerosols, and N95 respirators provide no
protection against gases of vapors; they both only act
as physical barrier against splashes and droplets hitting
the nose and mouth of the person. Surgical masks and
N95 respirators are hence both not recommended
for use.6
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Relevant guidelines need to be reviewed to check
whether the type of cabinet used warrants to wear a
mask or not.
A NIOSH approved disposable respirator mask
(an elastomeric half-mask with a multigas cartridge
and P100 particulate filter) should be used in case of
a spill or when cleaning the safety cabinet.6,7
5.3.3. Gowns. The gown used should have the following
characteristics: Long and closed at the neck - Long
sleeves with cuffs gripped at the wrist - Waterproof
material for the front and sleeves.6,7,12
A dedicated gown for CARL, distinct from gowns
used in other laboratories should be used.
Disposable over sleeve to protect the wrist and lower
arm should be used.
If an over sleeve and a plastic apron over the gown
are used and discarded after each manipulation, the
gown could be kept for further use.
The gown could be folded inside out and stored in a
plastic bag for further use.
White coats used in cytotoxic laboratories should be
hung horizontally to avoid cross contamination that
could result from hanging them on top of each other.
Each gown should be labelled with researcher’s name
to avoid the wrong coat being used.
University protocol or policy for washing lab coats
used during experiments with cytotoxic agents should
be followed (use of dedicated washrooms, dissolvable
bags, etc.) otherwise, the lab coats should be discarded
as cytotoxic waste.
5.3.4. Eye protection/face shields. Traditional safety labo-
ratory goggles should be used when in the laboratories
and offer acceptable protection.6,7 A face shield should
only be worn for managing spills.
5.3.5. Overshoes. Overshoes should be donned as soon
as the researcher enters the laboratory and should be
removed second last, right before removing the inner
pair of gloves, considered clean
5.3.6. Work mats. A work mat should be used in areas
where manipulation of cytotoxic material is taking
place, i.e. reconstitution within the BSC, vials/tubes/
syringes containing CA to ensure containment of
contamination.
The work mat should have 3 layers of absorbing
material on the top and a non-slip under layer.
5.3.7. Over sleeves. Over sleeves should be worn during
manipulation of cytotoxic material to minimise con-
tamination of gowns.12,13 These should be (1) imper-
meable to commonly listed cytotoxic drugs, (2) allow
comfortable manipulation, (3) have knitted cuffs for
added safety and to allow extending the outer pair of
gloves over the sleeves.
Using over sleeves helps reduce cost as the research-
er will be able to re-use the gown rather than discarding
it after each reconstitution.
5.3.8. Plastic aprons. These are usually polyethylene12
and should provide a protective barrier to accidental
spills or sprays
5.3.9. Removing PPE. Over sleeves should be rolled down
so that they are inside out when taken off, thus con-
taining any contamination on the inside.
When removing the outer gloves, the exterior cuff of
the first glove should be held and rolled down so to
become inverted inside out. While holding that
removed glove in the double-gloved hand, the second
glove should be rolled down and inverted inside out
over the first glove.
Gloves should be removed by touching the inside of
the cuff to avoid any contamination of the inner gloves.
All used PPE should be discarded as cytotoxic
waste.
5.3.10. Re-using PPE. Only the white coat could be reused
if “clean”, i.e. no visible contamination after the use of
over sleeves and plastic apron.
5.3.11. Washing facility for emergency management of splash/
spill. Eye bath and means of washing should be avail-
able at the CARL or temporary CARL where CAs are
handled. Anyone accessing the CARL or temporary
CARL should be advised to use the closest bathroom
if not available within the laboratory where they are
operating. Normal soap and water could be used to
wash
6. Occupational health
Universities could adapt the requirement of The Higher
Educational Occupational Physicians/Practitioners on
securing access to a specialist in occupational
medicine.14
6.1. Records
Records of employee exposure researching CAs should
be kept
6.2. Personal exposure monitoring
The standard practice dictates that there is no need for
health surveillance as long as the subject is not showing
any symptoms.
Routine surveillance is not evidence based, however,
a log of exposure during manipulation should be kept
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for submission to occupational health (for health sur-
veillance of chronic exposure) when needed.
In case of any spill or exposure, then appropriate
medical attention should be sought, and the incident
should be reported.
Any incident related to a cytotoxic or potentially
cytotoxic compound should be logged.
7. Environmental controls
7.1. Cleaning
By definition cytotoxic drugs interrupt cellular process-
es and thus will be harmful to organisms and in partic-
ular the aquatic environment.
A number of simple rules should be followed when
dealing with cytotoxic drug waste.
a. Liquid waste/Water used for cleaning (considered
contaminated) could be discarded into the sewage
as it is diluted and deactivated by addition of bleach
b. Liquid waste should be held in drums labelled
appropriately and removed using a licensed
contractor
c. Solid waste should be disposed of as “Hazardous
waste” and sharps disposed of in a sharps’ container
with the colour of the lid highlighting the cytotoxic
nature of the contents.
d. The disposal of cytotoxic drug waste should be out-
sourced to a company specialised in the disposal of
hazardous waste
e. CA waste should not be mixed with any non-
hazardous waste
f. Removal from the site should be through a licensed
contractor.
g. Labels used for such waste should be identified with
the European Waste Catalogue (EWC) codes of 18
01 03 or 18 01 08
h. A cytotoxic drug trail from laboratory to contractor
should be in place to ensure that the correct proce-
dures are being followed
i. Records could be maintained of how CAs are dis-
posed of from the laboratory and how much is being
removed over a set time period such as a week/
month etc.
j. Liquid spillages should be absorbed using tissues,
cloths etc. Residual material should be diluted with
copious amounts of detergent.
k. Appropriate PPE including double gloves, laborato-
ry coat and protective plastic apron, face shield (pre-
ferred to eye protection) should be worn when
dealing with a spillage irrespective of volume or
amount.
l. Records of occupational exposure should be kept for
up to 10 years. They should be electronic and stored
in a searchable and future proof format.
7.2. Transport of CA within university
Transport of CA within university (e.g. between labo-
ratories) should be carried while wearing a lab coat,
holding a spill kit, and with CA contained in a leak-
proof container
7.3. Transport of cytotoxics off university premises
The authorization for carrying cytotoxics in public
transport depends on the company and should be
checked accordingly (e.g. not allowed on Transport
for London).
The packaging should be well labelled, and the
researcher should follow the same packaging principles
as those described for transport within university prem-
ises (Section E- 2.Transport). Only a leak proof con-
tainer and spill kit should be used.
Whenever CAs are transported outside of the uni-
versity, the Carriage of dangerous goods regulations
should be referred to literature.15
8. Emergency procedure
There should be an ’out of hours’ procedure, with a
spill kit placed next to it, in addition to a risk analysis
documentation/Document of mitigation accessible at
the laboratory where the CAs are handled.
Researcher should complete “unattended working”
form for unattended experiments e.g. LC-MS with
clear details of drugs being used, amounts/concentra-
tions and contact details. This form should be dis-
played next to instrument and another copy lodged
with security or equivalent.
Likely emergency or problem scenarios should be
assessed and mitigating procedures outlined e.g.
power failure, chemical spillage, and evacuation of
building due to fire.
In case of any major incident, CARL researchers
should be aware of location of phone, fire alarms and
power isolation devices. For minor incident (e.g. spill-
age) CARL researchers should be aware of procedures
for dealing with it, contact details of supervisor and
logging the incident.
A clearly labelled cytotoxic spill kit should be kept
wherever cytotoxic medications are being prepared,
stored, or analysed.
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9. Assurance of compliance
9.1. Inspections
A structured inspection should be carried by a team
appointed as per the university guidance, for example
made up of the departmental safety officer and an
interested subject lead.
Inspections at the university should be carried
3 times per year or once per semester, then it should
be integrated within the general inspections of the uni-
versity health and safety.
There should be a reporting protocol that corre-
sponds to the university management structure
9.1.1. Store inspection. The aim of the store inspection
is to
• Ensure risk assessments are maintained and in use
• Ensure records are maintained and that CAs are
correctly recorded on entry and removal for use
• Ensure that CAs are securely stored
• Ensure knowledge of spill kit use and location
• Condition of transport of CAs within the site
9.1.2. Laboratory inspection. The aim of the laboratory
inspection is to
• Ensure Risk assessments are maintained and used
• Verify staff are trained on the manipulation of CAs
and equipment and that the training is recorded
• Ensure records of CAs used are maintained (records
as COSHH forms kept in laboratories)
• Ensure safe storage of CAs
• Ensure correct PPE used when CAs are in use
• Ensure correct disposal of CA waste
9.2. Audits
The audit should be carried infrequently (every
2-3 years)
9.2.1. Audit structure. Receiving relevant safety docu-
mentation detailing;
• The safety structure within the organisation and
management responsibilities
• Risk assessments controlling the working practices
and perceived hazards
• Training strategy for staff and management on
responsibilities, working practices and equipment
• The organisation of relevant safety committees
• Communication systems in place to disseminate
information
9.2.2. Audit team.
• Research team member, preferably the principle
investigator or senior team member from area
being audited
• Departmental safety officer
• Corporate safety representative
• External auditor either from another organisation or
department
• Appoint lead auditor
9.2.3. Methodology. Selected in depth interviews reflect-
ing the horizontal and vertical staffing structure with
the aim to verify the documentation received.
Meeting with senior managers to determine the
scope and time, date of audit etc. Determine who will
be audited and present an agreed timetable.
Select audit team members with specific responsibil-
ities during the audit
The scope may focus on one aspect of work carried
out with CAs or look at all aspects ranging from arrival
to disposal.
A debrief meeting with senior managers should be
held at the end of the audit detailing any immediate
and obvious findings followed by a written report.
Finally, a second meeting to agree objectives outlined
in the audit report with agreed timescales for imple-
menting the audit findings.
The audit should be considered as a constructive
process with recommendations for improvement
rather than a penalizing system.
9.2.4. Record keeping. An updated list of investigated
compounds in each laboratory should be screened by
technical/safety officer: Researchers should notify their
laboratory manager of the drug handled.
The researcher should have a log of the agents used
in the laboratory
9.2.5. Quality assurance. Wipe sample assessment should
be performed for proof of compliance; validated sam-
pling and analytical methods should be adapted from
reliable sources or determined beforehand.
The wipe sampling strategy depends on the nature,
frequency of use, and load of CA handled at the site; a
solvent or wetting agent is added to the surface or
wiping material and collected for analysis.
Wipe sample analysis is usually performed using gas
chromatography (GC), liquid chromatography (LC),
high-performance liquid chromatography (HPLC),
and ultra-performance liquid chromatography
(UPLC); all in combination with mass spectrometry
(MS) or tandem mass spectrometry (MS/MS).
Adequate PPEs should be donned during sampling of
the areas.16
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In this context, a novel device was recently intro-
duced to the market for qualitatively detecting the pres-
ence of hazardous agents on a given surface within few
minutes . Currently, kits are available for Methotrexate
and Doxorubicin with a lower limit of detection
(LLOD) of 0.1 ngml1 and for cyclophosphamide
with an LLOD of 0.5 ngml1.
Studies are needed to assess the appropriateness,
applicability, and sensitivity of this device in real
practice.
Conclusion
These recommendations were developed in order to
safeguard and minimize the prospective hazardous con-
sequences on the health of researchers and university
personnel in contact with CAs.
Despite the efforts invested to address all aspects of
handling CAs throughout its trajectory in university
premises, it remains challenging to envisage all related
circumstances. Hence, researchers and assigned author-
ities in universities should use these recommendations
while consulting their professional judgement, experi-
ence, and surely, national, state, and/or federal
regulations.
Practice implications
This is the first set of consensus recommendations for
CAs in academic research settings, however, a signifi-
cant proportion of the recommendation might apply to
the safe handling of other agents with questionable
occupational safety. Today, concerns from occupation-
al exposure is expanding beyond hazardous and cyto-
toxic agents to include antibiotics, and nanoparticles.
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